Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We know hereditary angioedema is a genetic ...
4d
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in ...
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, ...
Please provide your email address to receive an email when new articles are posted on . Attack rates fell for patients with and without C1 inhibitor deficiencies. Monthly attack rates fell from 2.35-2 ...
ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (PHVS) (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary ...
In the first oral presentation, KalVista presented data providing the rationale for the sebetralstat regimen for short-term prophylaxis (STP) for medical and dental procedures in people living with ...
Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema, ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results